Myc-Max Inhibitor Compounds Targeting DNA-Binding Domain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for targeting Myc-Max interactions in cancer therapy face challenges due to the intrinsically disordered nature of Myc and Max proteins, making it difficult to design effective small molecule inhibitors that can inhibit Myc-Max dimerization and bind with sufficient affinity and selectivity, and existing inhibitors suffer from rapid metabolism and low tumoral concentrations.
Innovation Solution
Development of specific compounds, such as VPC-70063 and VPC-70067, which modulate Myc-Max activity by binding to the DNA-binding domain of the Myc-Max complex, inhibiting transcriptional activity and cell proliferation, and inducing apoptosis in cancer cells, with improved potency and selectivity compared to previous compounds like 10058-F4 and 10074-G5.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional structure-based drug design approaches are used to target Myc, then the therapeutic approach is straightforward, but the intrinsically disordered nature of Myc and Max proteins makes it difficult to design effective small molecule inhibitors with sufficient affinity and selectivity
Solution Approach 1:
Instead of attempting to inhibit the disordered Myc-Max dimerization interface directly with small molecules (which has proven difficult), the patent inverts the approach by targeting the ordered DNA-binding domain of the Myc-Max complex. This inversion allows small molecules to bind to a structured, well-defined region (the DNA-binding domain) rather than the disordered interface, thereby achieving reliable inhibition while maintaining ease of drug design.
2Reliability
If existing Myc inhibitors are used, then some inhibition of Myc-Max activity is achieved, but the compounds suffer from rapid metabolism and low tumoral concentrations
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of inhibitor compounds to improve their metabolic stability. Specifically, the compounds are designed with structural features that resist metabolic degradation while maintaining their ability to bind to the Myc-Max DNA-binding domain. This allows the inhibitors to maintain effective concentrations in tumors for longer durations, thereby achieving both reliable Myc-Max inhibition and improved metabolic stability.
3Productivity
If Myc-Max dimerization is inhibited to stop cancer growth, then tumor proliferation is controlled, but the disordered nature of the proteins makes it challenging to achieve sufficient binding affinity and selectivity
Solution Approach 1:
The patent extracts the DNA-binding domain from the overall Myc-Max complex as a separate, targetable entity. By focusing specifically on this ordered domain rather than attempting to target the entire disordered complex, the invention achieves both effective cancer growth control and high binding affinity with selective inhibition. The small molecules are designed to bind specifically to the DNA-binding domain, which has a well-defined structure amenable to precise molecular recognition.
Data Source
AI summary
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.